Camilleri, M. (2025). GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing? Obesity. https://doi.org/10.1002/oby.24215
Cencioni, C., Malatesta, S., Benedetti, V. V., Licursi, V., Perfetto, L., Conte, F., Ranieri, D., Bartolazzi, A., Kunkl, M., Tuosto, L., Larghi, A., Piro, G., Agostini, A., Tortora, G., Corbo, V., Carbone, C., & Spallotta, F. (2025). The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. Journal of Experimental & Clinical Cancer Research, 44(1). https://doi.org/10.1186/s13046-024-03263-w
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., De Torres-Sánchez, A., García-De-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145
Ito, H., Ito, K., Tanaka, M., Hokamura, M., Tanaka, M., Kusano, E., Kondo, J., Izutsu, T., Matsumoto, S., Inoue, H., Antoku, S., Yamasaki, T., Mori, T., & Togane, M. (2022). Constipation Is a Frequent Problem Associated with Vascular Complications in Patients with Type 2 Diabetes: A Cross-sectional Study. Internal Medicine, 61(9), 1309–1317. https://doi.org/10.2169/internalmedicine.7676-21
Lai, S., Zhu, C., Zhou, X., Zeng, Q., Huang, L., Cao, X., Zhou, Q., Zhong, Y., Huang, J., Liu, J., Zeng, G., & Chen, H. (2024). Effect of physical activity on the association between diet and constipation: evidence from the National Health and Nutrition Examination Survey 2007-2010. Journal of Neurogastroenterology and Motility, 30(3), 322–331. https://doi.org/10.5056/jnm23134
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/nejmoa1607141